aTyr Pharma, Inc. (ATYR)
0.5035
+0.01
(+2.13%)
USD |
NASDAQ |
Sep 03, 16:00
0.5001
0.00 (0.00%)
After-Hours: 07:30
aTyr Pharma Enterprise Value : 3.074M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | 3.074M |
| September 02, 2026 | 2.044M |
| September 01, 2026 | 0.4256M |
| August 31, 2026 | 5.840M |
| August 28, 2026 | 6.654M |
| August 27, 2026 | 8.086M |
| August 26, 2026 | 7.733M |
| August 25, 2026 | 9.597M |
| August 24, 2026 | 5.673M |
| August 21, 2026 | 2.878M |
| August 20, 2026 | 3.025M |
| August 19, 2026 | 5.948M |
| August 18, 2026 | 3.133M |
| August 17, 2026 | 4.585M |
| August 14, 2026 | 8.518M |
| August 13, 2026 | 7.929M |
| August 12, 2026 | 6.684M |
| August 11, 2026 | 6.066M |
| August 10, 2026 | 5.565M |
| August 07, 2026 | 3.849M |
| August 06, 2026 | 2.927M |
| August 05, 2026 | 5.575M |
| August 04, 2026 | 5.595M |
| August 03, 2026 | 1.946M |
| July 31, 2026 | 1.328M |
| Date | Value |
|---|---|
| July 30, 2026 | 0.769M |
| July 29, 2026 | 1.063M |
| July 28, 2026 | 2.142M |
| July 27, 2026 | 1.711M |
| July 24, 2026 | 0.1118M |
| July 23, 2026 | 2.544M |
| July 22, 2026 | 1.456M |
| July 21, 2026 | 1.348M |
| July 20, 2026 | 1.397M |
| July 17, 2026 | 3.692M |
| July 16, 2026 | 4.290M |
| July 15, 2026 | 6.095M |
| July 14, 2026 | 1.358M |
| July 13, 2026 | 3.133M |
| July 10, 2026 | 7.086M |
| July 09, 2026 | 10.74M |
| July 08, 2026 | 16.77M |
| July 07, 2026 | 13.14M |
| July 06, 2026 | 17.83M |
| July 02, 2026 | 11.80M |
| July 01, 2026 | 11.54M |
| June 30, 2026 | 12.23M |
| June 29, 2026 | 0.5302M |
| June 26, 2026 | -3.284M |
| June 25, 2026 | -0.1267M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| MetaVia, Inc. | -0.3577M |
| Alnylam Pharmaceuticals, Inc. | 35.05B |
| ACADIA Pharmaceuticals, Inc. | 3.913B |
| Anika Therapeutics, Inc. | 267.88M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.31M |
| Total Expenses (Quarterly) | 10.31M |
| EPS Diluted (Quarterly) | -0.1051 |
| Earnings Yield | -123.7% |
| Normalized Earnings Yield | -123.65 |